New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers
A substudy from the REBOOT trial published at the European Heart Journal shows that women treated with Beta-blockers had a higher risk of death, reinfarction, or hospitalization for heart failure compared to women not receiving the drug
2025-08-30
(Press-News.org) A major new analysis from REBOOT (Treatment with Beta-blockers after Myocardial Infarction without Reduced Ejection Fraction) clinical trial, an international study coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published at the European Heart Journal has revealed important sex-specific differences in the effects of beta-blockers following heart attacks, raising questions about long-standing treatment practices.
REBOOT, presented in a Hotline session of the ESC congress in Madrid, is the largest contemporaneous trial testing the effect of beta-blockers in patients who survive myocardial infarction without a moderate or severe deterioration of their cardiac function (i.e. left ventricular ejection fraction greater than 40%). 8,505 patients were included across 109 hospitals in Spain and Italy. While the proportion of women in the trial was not high (something common in most myocardial infarction trials), the total number of women is the largest ever included in a trial testing beta-blockers after infarction, providing high power to the analysis performed. Patients were randomly assigned to receive Beta-blockers—a commonly prescribed drug—or no beta-blocker, while continuing to receive standard post-heart attack care. Patients were followed for a median of nearly four years.
The analysis uncovers notable sex-specific differences: while men experienced no benefit or risk when treated with beta-blockers, women treated with Beta-blockers had a significant increased risk of death, reinfarction, or hospitalization for heart failure compared to women not receiving the drug. Women treated with beta-blockers had a 2.7% higher absolute risk of mortality than those not treated with beta-blockers during the 3.7 years of follow-up of the study. The elevated risk when treated with beta-blockers was restricted to women with a complete normal cardiac function after infarction (i.e. left ventricular ejection fraction of 50% or higher). Those with a mild deterioration in cardiac function did not have an excess risk of adverse outcomes when treated with beta-blockers.
Another important finding from this pre-specified analysis of the REBOOT trial is that women presenting with infarction had a worse cardiovascular profile. They were older, had more comorbidities (including higher prevalence of hypertension diabetes and dyslipidemia), and more frequently experienced heart attacks without obstructive coronary arteries (6% vs 2% in men). In addition, while overall prescription rates of secondary prevention interventions were high for all patients in the trial, women were less often prescribed some guideline-recommended therapies such as antiplatelets, statins, angiotensin-converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARBs) or cardiac rehabilitation. Of note, overall, women had a significantly worse prognosis than men (mortality across study duration was 4.3% in women vs. 3.6% in men). The Principal Investigator of the REBOOT trial, Dr. Borja Ibáñez, CNIC Scientific Director, cardiologist at Hospital Universitario Fundación Jiménez Díaz, and member of the CIBERCV, says “these findings confirm previous observational data but in a rigorous prospective trial: women presenting with infarction have worse cardiovascular profile and, more importantly, have worse prognosis than men. Our data also shows that they respond differently to a commonly prescribed intervention, beta-blockers in this case”.
Xavier Rosselló, scientist at CNIC, cardiologist at University Hospital Son Espases in Mallorca and another leader of the REBOOT trial emphasizes that "Our findings suggest that a one-size-fits-all approach may not be appropriate and that sex-specific considerations are crucial for cardiovascular interventions prescriptions."
The REBOOT trial was coordinated by the CNIC, in collaboration with the Mario Negri Institute for Pharmacological Research in Milano, Italy. As the largest independent study of its kind, it provides critical insights into how modern post-heart attack treatments should consider patient sex, heart function, and dosing strategies. "In many cases, prescribing Beta-blockers to women after uncomplicated heart attack may do more harm than good," Dr. Ibáñez added. "Clinicians should carefully weigh the risks and benefits, and consider dose adjustments or alternative therapies when treating female patients."
The trial’s results underscore the importance of personalizing post-heart attack therapy. By highlighting how sex-specific factors influence the safety and effectiveness of commonly used drugs, REBOOT could reshape guidelines and improve outcomes for women worldwide.
Dr. Valentín Fuster, CNIC General Director, President of Mount Sinai Fuster Heart Hospital, and another investigator of REBOOT trial, notes: “We have been investigating sex-differences in cardiovascular disease for a long time. We already knew that cardiovascular disease presentation is different in women and men, and this study significantly adds to this knowledge by showing that response to medications is not necessarily equal in women and men. This study should spark the much-needed sex-specific approach for cardiovascular disease”. The REBOOT trial was funded by the CNIC, an affiliate center of the Carlos III Health Institute (ISCIII), an executive agency of the Spanish Ministry of Science, Innovation and Universities. The clinical trial was carried out with the collaboration of the Spanish Society of Cardiology (SEC), and CIBERCV.
About the CNIC
The CNIC is an affiliate center of the Carlos III Health Institute (ISCIII), an executive agency of the Spanish Ministry of Science, Innovation, and Universities. Directed by Dr. Valentín Fuster, the CNIC is dedicated to cardiovascular research and the translation of the knowledge gained into real benefits for patients. The CNIC has been recognized by the Spanish government as a Severo Ochoa center of excellence (award CEX2020-001041-S, funded by MICIN/AEI/10.13039/501100011033). The center is financed through a pioneering public-private partnership between the government (through the ISCIII) and the Pro-CNIC Foundation, which brings together 11 of the most important Spanish private companies.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-08-30
Madrid, August 30, 2025. An international clinical trial coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with the Mario Negri Institute for Pharmacological Research in Milan, has found that beta-blockers—drugs commonly prescribed for a range of cardiac conditions—offer no clinical benefit for patients who have had an uncomplicated myocardial infarction (i.e., without deterioration of the heart function after the event).
The findings—published in two articles in The New England Journal of Medicine and The Lancet and presented today during a “Hot Line” ...
2025-08-30
About The Study: Randomization systolic blood pressure (SBP) was associated with the survival benefit of microaxial flow pump treatment, with the most hypotensive patients deriving the largest survival benefit. Early SBP may help identify patients most likely to gain a net benefit from microaxial flow pump treatment. Findings are hypothesis generating.
Corresponding Author: To contact the corresponding author, Astrid Duus Mikkelsen, MD, email astrid.duus.mikkelsen@reigonh.dk.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including ...
2025-08-30
Beta blockers—drugs commonly prescribed for a range of cardiac conditions, including heart attacks—provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with preserved heart function. Beta blockers have been the standard treatment for these patients for 40 years.
This is a breakthrough discovery from the “REBOOT Trial” with senior investigator Valentin Fuster, MD, PhD, President of Mount Sinai Fuster Heart Hospital and General Director of Spain’s Centro Nacional de Investigaciones Cardiovasculares ...
2025-08-29
Glaciers across High Mountain Asia are losing more than 22 gigatons of ice per year—the equivalent to nearly 9 million Olympic swimming pools, according to research from the University of Utah and Virginia Tech. The impact of a warming climate on glacial loss is undisputed—this new study provides the first evidence that seasonal shifts in rainfall and snowfall patterns, particularly of the South Asian monsoons, are also exacerbating glacier melting across the region.
“These findings highlight that glaciers dominated by the South Asian monsoons, such as the Central Himalaya, ...
2025-08-29
LA JOLLA (August 29, 2025)—A plant’s number one priority is to grow—a feat that demands sunlight, nutrients, and water. If just one of these three inputs is missing, like water in a drought, growth halts. You might then think that at the end of that drought, the plant would jump right back into growing. Instead, its priorities shift.
Salk plant biologists used advanced single-cell and spatial transcriptomic techniques to look closely at how a small, flowering plant called Arabidopsis thaliana recovers after drought. They discovered that immunity became the plant’s number one priority during this ...
2025-08-29
The stereotypical employee may be at a desk in front of a computer screen working a nine-to-five, but for many employees, the work day is filled with manual labor, hazardous environments and late-night shifts. Your local garbage collector, for example, is someone with a job that society might consider “dirty,” both literally and socially.
Scott Dust, PhD, professor in the management department at the University of Cincinnati Carl H. Lindner College of Business, worked with doctoral candidates Sodiq Babatunde and Ben Fagan to analyze the impact of stress and ...
2025-08-29
Picture this: You’re stuck in traffic on a summer afternoon, checking the weather app on your phone as dark storm clouds roll in. You might think about power outages or possible flooding, but you probably don’t think about how every lightning bolt that flashes across the sky also emits a gas, nitrogen oxide (NO), that is also emitted in the exhaust from your car’s engine.
Yet, that’s exactly what occurs during a thunderstorm. For the first time, scientists from the University of Maryland were able to detect lightning and its impact on air quality using high-frequency ...
2025-08-29
Hormonal birth control is a fact of life for millions of women. In the U.S. alone, more than 60 million women of reproductive age have used contraceptives according to the Centers for Disease Control and Prevention, most often to prevent pregnancy but also to manage conditions such as endometriosis, polycystic ovary syndrome and irregular cycles.
And as many women will attest, these drugs can affect more than the body. Mood changes, weight fluctuations and emotional ups and downs are common stories women ...
2025-08-29
The Philippines, like other tropical countries, is known more for its balmy climate than for hailstorms. But a new Philippine study—the first of its kind—has found that the country’s hottest days are, in fact, more likely to produce hail.
Hailstorms are so few and far between in the Philippines that, even in an age of pervasive social media updates, they are still met with amazement and astonishment.
“Most people are surprised when hail happens because it is relatively rare in the Philippines,” ...
2025-08-29
The European Society of Cardiology (ESC) has selected Roxana Mehran, MD, Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai, as a winner of the organization’s top honor. Dr. Mehran was presented with the “ESC Gold Medal” during a special ceremony at the ESC Congress in Madrid on Friday, August 29.
The ESC Gold Medal recognizes exceptional scientists for their contributions to cardiovascular ...
LAST 30 PRESS RELEASES:
[Press-News.org] New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers
A substudy from the REBOOT trial published at the European Heart Journal shows that women treated with Beta-blockers had a higher risk of death, reinfarction, or hospitalization for heart failure compared to women not receiving the drug
